Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value [Seeking Alpha]
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.